Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24241365 | 0.89 | ALDH1A1 (0.52) | ALDH1A1LMNANPC1RAB9ACYP19A1 | |
| SCHEMBL20477480 | 0.86 | ALDH1A1 (0.56) | ALDH1A1LMNANPC1RAB9ACYP19A1 | |
| SCHEMBL20477406 | 0.85 | KMT2A (0.47) | ALDH1A1LMNANPC1RAB9AMAPK1 | |
| SCHEMBL20477298 | 0.84 | ALDH1A1 (0.54) | ALDH1A1LMNANPC1RAB9ACYP19A1 | |
| SCHEMBL20477301 | 0.84 | ALDH1A1 (0.54) | ALDH1A1LMNANPC1RAB9ACYP19A1 | |
| SCHEMBL28740607 | 0.83 | ALDH1A1 (0.53) | ALDH1A1LMNANPC1RAB9ACYP19A1 | |
| SCHEMBL20477266 | 0.83 | ALDH1A1 (0.53) | ALDH1A1LMNANPC1RAB9ACYP19A1 | |
| SCHEMBL20477335 | 0.83 | SMN1; SMN2 (0.56) | ALDH1A1LMNANPC1RAB9ACYP19A1 | |
| SCHEMBL20477366 | 0.83 | ALDH1A1 (0.43) | ALDH1A1LMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL25604980 | 0.83 | ALDH1A1 (0.57) | ALDH1A1LMNANPC1RAB9ACYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331707-A1 | PROGRAMMED CELL NECROSIS INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20230331707-A1 | PROGRAMMED CELL NECROSIS INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20230331707-A1 | PROGRAMMED CELL NECROSIS INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2023-10-19 | — | — | US | disclosed |
| EP-4215532-A1 | PROGRAMMED CELL NECROSIS INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (CN) | 2023-07-26 | — | — | EP | disclosed |
| EP-4215532-A1 | PROGRAMMED CELL NECROSIS INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (CN) | 2023-07-26 | — | — | EP | disclosed |
| CN-108431004-B | Heterocyclic compounds | 武田药品工业株式会社 | 2021-02-12 | — | — | CN | disclosed |
| US-10787462-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-09-29 | — | — | US | disclosed |
| EP-3366684-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-09-02 | — | — | EP | disclosed |
| US-20180319819-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-11-08 | — | — | US | disclosed |
| EP-3366684-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787462-B2 | Heterocyclic compound | RIPK1, RIPK4, RIPK3 | ALDH1A1 2773/4885LMNA 2277/4885NPC1 44/4885 |
| US-20230331707-A1 | PROGRAMMED CELL NECROSIS INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | RIPK1, RIPK4, RIPK3 | ALDH1A1 4259/4885LMNA 1492/4885NPC1 600/4885 |
| US-20180319819-A1 | HETEROCYCLIC COMPOUND | RIPK1, RIPK4, RIPK3 | ALDH1A1 2773/4885LMNA 2277/4885NPC1 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.